Clarient, Inc. (CLRT) rated Buy with price target $4 by The Benchmark Company
The Benchmark Company rated Buy Clarient, Inc. (NASDAQ: CLRT) on 05/26/2010, when the stock price was $2.85. Since
then, Clarient, Inc. has lost 7.02% as of 12/22/2011's recent price of $2.65. If you would have followed this The Benchmark Company's recommendation on CLRT, you would have lost 7.01% of your investment in 575 days.
CVS/Caremark is the nation's premier integrated pharmacy services provider, combining one of the nation's leading pharmaceutical services companies with the country's largest pharmacy chain. The company fills or manages more than one billion prescriptions per year, more than any other pharmacy services provider. CVS/Caremark drives value for pharmacy services customers by effectively managing pharmaceutical costs and improving healthcare outcomes through its six thousand two hundred CVS/pharmacy stores; its pharmacy benefit management, mail order and specialty pharmacy division, Caremark Pharmacy Services; its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com.
The Benchmark Company
's Equity Research team is one of the most experienced on the Street. Our analysts average almost two decades of sell-side research experience and many have substantial experience in the industries they cover as well. Our people give us the ability to deliver insightful and unique research seasoned by the experience of having lived through multiple bull and bear markets, and having covered their companies longer than most of their peers.